Drug Trial Radar · NCT04990310
Single Dose Absorption, Distribution, Metabolism, and Excretion Study of [14C]-CORT113176 in Healthy Male Participants
Last checked: Nov 19, 2026Latest source record: Nov 24, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
6
Actual
Start
Aug 18, 2021
Primary completion
Sep 20, 2021
Study completion Sep 20, 2021
Sponsor
- Lead sponsor
- Corcept TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Aug 4, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- No
- Who can join
- Male only, from 30 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study will evaluate the mass balance recovery and metabolite profile, and will identify metabolite structures following a single oral dose of \[14C\]-CORT113176 in healthy male participants.
Conditions
- Healthy
Interventions
[14C]-CORT113176Drug
\[14C\]-CORT113176 450 mg lipid formulation capsule for oral administration containing not more than 3.37 megaBequerel 14C.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mass Balance Recovery in Excreta After a Single Dose of [14C]-CORT113176Time frame: Until the mass balance criteria for all participants have been met (estimated up to 28 days)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Site 01
Ruddington, Nottingham, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.